ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
On March 7, 2017, EnteroMedics Inc. (the Company) issued a press
release announcing its financial results for the three months and
full year ended December 31, 2016. The Company also announced
that it will be hosting a conference call to discuss corporate
updates and its financial results for the three months and full
year ended December 31, 2016 at 11:00 a.m. Eastern Time on March
7, 2017.A copy of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by
reference.
The information furnished herewith to Item 2.02 of this Current
Report and in Exhibit 99.1 hereto is being furnished in
accordance with General Instruction B.2 of Form 8-K and shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed to be incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of any general
incorporation language in such filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 7, 2017. |
About ENTEROMEDICS INC. (NASDAQ:ETRM)
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system. ENTEROMEDICS INC. (NASDAQ:ETRM) Recent Trading Information
ENTEROMEDICS INC. (NASDAQ:ETRM) closed its last trading session 00.00 at 6.43 with 493,982 shares trading hands.
